By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Asterias Biotherapeutics 

6300 Dumbarton Circle

Fremont  California  94555  U.S.A.
Phone: 510-456-3800 Fax: n/a



Company News
Asterias Biotherapeutics Release: Update On Full Six-Patient Cohort Confirms Patients With Complete Paralysis Can Experience Meaningful Recovery Of Function By Six Months Following AST-OPC1 Treatment 3/21/2017 6:41:51 AM
Asterias Biotherapeutics To Report Fourth Quarter And Full Year Results On March 28, 2017 3/7/2017 11:07:20 AM
Asterias Biotherapeutics Extends The Expiration Date Of Certain Warrants And Provides Update On Cash Position 2/3/2017 7:01:09 AM
Asterias Biotherapeutics Release: Biotech Announces Additional Motor Function Improvement At 6-Months And 9-Months Following Treatment With AST-OPC1 In Patients With Complete Cervical Spinal Cord Injuries 1/24/2017 11:52:48 AM
Asterias Biotherapeutics Announces Conference Call To Discuss 6-Month Efficacy Data From AST-OPC1 SCiStar Study 1/18/2017 10:46:32 AM
Asterias Biotherapeutics Announces Successful Commencement Of Operations At New GMP Manufacturing Facility For AST-OPC1 1/9/2017 9:57:17 AM
Ryan Chavez Appointed Chief Financial Officer Of Asterias Biotherapeutics 11/17/2016 8:31:30 AM
Asterias Biotherapeutics Reports Third Quarter Results And Accelerating Enrollment Of AST-OPC1 SCiStar Phase 1/2a Study 11/15/2016 11:09:47 AM
Asterias Biotherapeutics Announces Treatment Of First Spinal Cord Injury Patient With Maximum Dose Of AST-OPC1 In SCiStar Clinical Trial 11/9/2016 11:31:30 AM
Asterias Biotherapeutics To Report Third Quarter Results On November 14, 2016 11/4/2016 9:11:37 AM